Skip to main content
. 2022 Aug 3;52:101585. doi: 10.1016/j.eclinm.2022.101585

Figure 3.

Figure 3

Average geometric mean antibody titre (GMT) for A) HPV-16, B) HPV-18, C) HPV-6, D) HPV-11 over time after administration of the quadrivalent vaccine in different PLHIV study populations (children: <18, adults: ≥18, and mix: both children & adults), stratified by baseline HPV status and type of test (Ns = 11 trials). On each panel, each line (or unique data point when only one time point was reported) is the mean from a different study. Ns on each panel indicate the number of studies included. Arrows indicate timing of vaccine doses. Dotted line indicates cut-off value for seropositivity for the cLIA assay. Mean (range) GMT levels (excluding neutralization assay results) at 28 weeks across studies are higher for HPV-16 (mean: 2239, range 504-5173 mMu/ml).